2008
DOI: 10.1016/j.critrevonc.2007.12.006
|View full text |Cite
|
Sign up to set email alerts
|

Management of Frail and Not-Frail elderly cancer patients in a hospital-based geriatric oncology program

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
60
0

Year Published

2009
2009
2021
2021

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 59 publications
(64 citation statements)
references
References 29 publications
3
60
0
Order By: Relevance
“…More than half of the patients had a disability on the IADL scale and more than one-third on the ADL scale, values similar to those reported elsewhere. 22 No difference was found between patients evaluated before versus during cancer therapy, although one might expect to find more dependency among the former patients. One study of patients in a senior adult oncology program showed only a weak correlation between comorbidity and functional status.…”
Section: Discussionmentioning
confidence: 94%
“…More than half of the patients had a disability on the IADL scale and more than one-third on the ADL scale, values similar to those reported elsewhere. 22 No difference was found between patients evaluated before versus during cancer therapy, although one might expect to find more dependency among the former patients. One study of patients in a senior adult oncology program showed only a weak correlation between comorbidity and functional status.…”
Section: Discussionmentioning
confidence: 94%
“…Although there were no differences in the use of the "elderlyfriendly" treatment among the frail and nonfrail (40% of frail patients and 39% of nonfrail patients), in the dose reduction greater than or equal to 25% (37.5% vs. 31.2%), in 3-to 4-grade toxicity (52.5% vs. 58.4%), there were remarkable differences between the groups in the percentages of premature interruption of treatment because of toxicity or the patient's refusal (42.5% vs. 15.6%) and the deaths within 30 days of the last dosage of the chemotherapy (22.5% vs. 3.9%). This demonstrates that the frail patients had obtained benefits from the treatment that were notably lesser not only in terms of tumor response (21.2% vs. 44.3% in 94 evaluated patients) but also in terms of clinical benefits (22.6% vs. 45.8% in 90 evaluated patients) 15 .…”
Section: Dear Editormentioning
confidence: 96%
“…On the other hand, standard protocols may lead to increased risk of toxicity and overtreatment for some patients. 70 Moreover, cancer stage may sometimes be underestimated if patients' nonspecific symptoms are attributed to comorbid conditions or the ageing process. 10 Optimal functional status represents a critical outcome in older cancer patients.…”
Section: Treatment Outcomesmentioning
confidence: 99%